Med Clin (Barc) 2020 Jan 28

Incidence of malignancy in a Spanish cohort of patients infected by the human immunodeficiency virus.

Cañas-Ruano E, Martín-Castillo M, Raventós B, Burgos J, Curran A, Navarro J, García J, Suanzes P, Ribera E, Falcó V

A higher incidence of malignancies has been described in patients with HIV infection compared to the general population. ... Read More

Source: PubMed

Int. J. Cancer 2020 Jan 31

Cause-specific mortality after diagnosis of cancer among HIV-positive patients: a collaborative analysis of cohort studies.

Trickey A, May MT, Gill MJ, Grabar S, Vehreschild J, Wit FW, Bonnet F, Cavassini M, Abgrall S, Berenguer J, Wyen C, Reiss P, Grabmeier-Pfistershammer K, Guest JL, Shepherd L, Teira R, d'Arminio Monforte A, Del Amo J, Justice A, Costagliola D, Sterne JA

People living with HIV (PLHIV) are more likely than the general population to develop AIDS-defining malignancies (ADMs) and several non-ADMs (NADMs). ... Read More

Source: PubMed

Science 2020 Jan 30

Structural basis of second-generation HIV integrase inhibitor action and viral resistance.

Cook NJ, Li W, Berta D, Badaoui M, Ballandras-Colas A, Nans A, Kotecha A, Rosta E, Engelman AN, Cherepanov P

Despite worldwide prescription, the mechanistic basis for superiority of second-generation HIV integrase (IN) strand transfer inhibitors (INSTIs) is p ... Read More

Source: PubMed

PLoS ONE

Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans.

Zhao LP, Fiore-Gartland A, Carpp LN, Cohen KW, Rouphael N, Fleurs L, Dintwe O, Zhao M, Moodie Z, Fong Y, Garrett N, Huang Y, Innes C, Janes HE, Lazarus E, Michael NL, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, De Rosa SC, Corey L, Gray GE, Seaton KE, Yates NL, McElrath MJ, Frahm N, Tomaras GD, Gilbert PB

HIV vaccine trials routinely measure multiple vaccine-elicited immune responses to compare regimens and study their potential associations with protec ... Read More

Source: PubMed